Previous 10 | Next 10 |
2024-05-08 09:54:58 ET More on Clene Seeking Alpha’s Quant Rating on Clene Historical earnings data for Clene Financial information for Clene Read the full article on Seeking Alpha For further details see: Clene GAAP EPS of -$0.09
Data from long-term extension of Phase 2 VISIONARY-MS clinical trial of CNM-Au8 ® demonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p<0.05) Peer-reviewed publication characterized the protein co...
Researchers from The Ohio State University have found that disturbed neuronal activity may cause metabolism issues in individuals who suffer spinal-cord injuries. Findings from an animal study suggest that heart attacks, diabetes and vascular conditions that typically affect patients postspin...
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. Rob Ethe...
Long-term extension of the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 exhibited significant evidence of repair and remyelination across multiple paraclinical endpoints (change from original baseline, p < 0.05) Significantly enhanced clinical outcomes were associated with long-term daily ...
LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN , a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceu...
CNM-Au8 is an oral suspension with demonstrated activity in restoring neuronal health and function by increasing energy production and utilization Treatment with CNM-Au8 investigated in clinical trials adjunctive to standard-of-care exhibits no known drug interactions, and aims to enhance funct...
2024-04-17 17:30:02 ET Benchmark analyst issues UNDERPERFORM recommendation for CLNN on April 17, 2024 04:02PM ET. The previous analyst recommendation was Underperform. CLNN was trading at $0.3396 at issue of the analyst recommendation. The overall analyst consensus : BU...
Clene (NASDAQ: CLNN) , a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., announced that results from a phase 2 Visionary-MS long-term extension (“LTE”) study have been presented at the 2024 American Academy of Neurology (ȁ...
2024-04-17 06:55:40 ET DENVER, Colo., Apr 17, 2024 ( 247marketnews.com )- Clene Inc. (Nasdaq: CLNN ) presented Phase 2 VISIONARY-MS long term extension (LTE) study results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver. The improved clinical, functional, an...
News, Short Squeeze, Breakout and More Instantly...
Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a...
Latest figures from the World Health Organization show that more than 8.5 million individuals around the globe are living with Parkinson’s disease . This disease is the fastest-growing neurodegenerative disorder globally, with the number of individuals with this illness more than doubli...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 106.5% to $1.38 on volume of 71,739,314 shares Renalytix plc (RNLX) rose 41.4% to $0.4269 on volume of 54,892,134 shares Maxeon Solar Technologies Ltd. (MAXN) fell 7.4% to $0.1951 on volume of 45...